Overall-survival benefit persisted at five years
Among 970 untreated patients with unresectable advanced, recurrent or metastatic ESCC, both nivolumab-containing regimens maintained an overall-survival advantage versus chemotherapy alone.
Five-year survival in tumor-cell PD-L1 ≥1%
Nivolumab + chemotherapy 12%; nivolumab + ipilimumab 18%; chemotherapy 7%.
PFS differed by regimen
Nivolumab + chemotherapy improved progression-free survival, while nivolumab + ipilimumab did not show a PFS improvement versus chemotherapy.
Official source
Research, clinical trials and approved treatments are presented separately. This page is general information, not individual medical advice.